Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Salim S. Virani; Julia M. Akeroyd; Vijay Nambi; Paul A. Heidenreich; Pamela B. Morris; Khurram Nasir; Erin D. Michos; Vera A. Bittner; Laura A. Petersen; Christie M. Ballantyne

doi:10.1161/CIRCULATIONAHA.117.028503

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Salim S. Virani
, Julia M. Akeroyd
, Vijay Nambi
, Paul A. Heidenreich
, Pamela B. Morris
, Khurram Nasir
, Erin D. Michos
, Vera A. Bittner
, Laura A. Petersen
, Christie M. Ballantyne

Research output: Contribution to journal › Letter › peer-review

59 Citations (Scopus)

Original language	English (UK)
Pages (from-to)	2572-2574
Number of pages	3
Journal	Circulation
Volume	135
Issue number	25
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.117.028503
Publication status	Published - 20 Jun 2017
Externally published	Yes

Keywords

cardiovascular disease
cholesterol
lipids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.117.028503

Cite this

Virani, S. S., Akeroyd, J. M., Nambi, V., Heidenreich, P. A., Morris, P. B., Nasir, K., Michos, E. D., Bittner, V. A., Petersen, L. A., & Ballantyne, C. M. (2017). Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs. Circulation, 135(25), 2572-2574. https://doi.org/10.1161/CIRCULATIONAHA.117.028503

Virani, Salim S. ; Akeroyd, Julia M. ; Nambi, Vijay et al. / Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) : Insights from the Department of Veterans Affairs. In: Circulation. 2017 ; Vol. 135, No. 25. pp. 2572-2574.

@article{a452017e3f7644c7b99dc07508b5e289,

title = "Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs",

keywords = "cardiovascular disease, cholesterol, lipids",

author = "Virani, \{Salim S.\} and Akeroyd, \{Julia M.\} and Vijay Nambi and Heidenreich, \{Paul A.\} and Morris, \{Pamela B.\} and Khurram Nasir and Michos, \{Erin D.\} and Bittner, \{Vera A.\} and Petersen, \{Laura A.\} and Ballantyne, \{Christie M.\}",

year = "2017",

month = jun,

day = "20",

doi = "10.1161/CIRCULATIONAHA.117.028503",

language = "English (UK)",

volume = "135",

pages = "2572--2574",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "25",

}

Virani, SS, Akeroyd, JM, Nambi, V, Heidenreich, PA, Morris, PB, Nasir, K, Michos, ED, Bittner, VA, Petersen, LA & Ballantyne, CM 2017, 'Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs', Circulation, vol. 135, no. 25, pp. 2572-2574. https://doi.org/10.1161/CIRCULATIONAHA.117.028503

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs. / Virani, Salim S.; Akeroyd, Julia M.; Nambi, Vijay et al.
In: Circulation, Vol. 135, No. 25, 20.06.2017, p. 2572-2574.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)

T2 - Insights from the Department of Veterans Affairs

AU - Virani, Salim S.

AU - Akeroyd, Julia M.

AU - Nambi, Vijay

AU - Heidenreich, Paul A.

AU - Morris, Pamela B.

AU - Nasir, Khurram

AU - Michos, Erin D.

AU - Bittner, Vera A.

AU - Petersen, Laura A.

AU - Ballantyne, Christie M.

PY - 2017/6/20

Y1 - 2017/6/20

KW - cardiovascular disease

KW - cholesterol

KW - lipids

UR - https://www.scopus.com/pages/publications/85020903486

U2 - 10.1161/CIRCULATIONAHA.117.028503

DO - 10.1161/CIRCULATIONAHA.117.028503

M3 - Letter

C2 - 28465286

AN - SCOPUS:85020903486

SN - 0009-7322

VL - 135

SP - 2572

EP - 2574

JO - Circulation

JF - Circulation

IS - 25

ER -

Virani SS, Akeroyd JM, Nambi V, Heidenreich PA, Morris PB, Nasir K et al. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs. Circulation. 2017 Jun 20;135(25):2572-2574. doi: 10.1161/CIRCULATIONAHA.117.028503

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Keywords

UN SDGs

Access to Document

Other files and links

Cite this